Allergan Finance LLC
DelistedCIK 884629fmd_0456R97AP3VAXR99NZ5SZSTBBKManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2008 to Sep 30, 2013, 19 periods
| Line item | FY2008 | FY2009 | FY2010 | FY2011 | FY2012 |
|---|---|---|---|---|---|
| Total revenues | – | 2,793 | 3,567 | 4,584 | 5,915 |
| Cost of revenue | 1,503 | 1,597 | 1,999 | 2,565 | 3,390 |
| Realized investment gains (losses) | 10 | (1) | 26 | 1 | 70 |
| Gross profit | – | 1,196 | 1,568 | 2,020 | 2,525 |
| Research and development | 170 | 197 | 296 | 295 | 402 |
| Selling, general and administrative | 423 | 520 | 756 | 755 | 1,171 |
| Operating income | 358 | 384 | 305 | 536 | 321 |
| Interest expense | 28 | 34 | 84 | 82 | 117 |
| Interest and investment income | 9 | 5 | 2 | 2 | 3 |
| Other non-operating income (expense) | 0 | (21) | (55) | (80) | (76) |
| Income before taxes | 358 | 363 | 251 | 456 | 245 |
| Income tax expense | 120 | 141 | 67 | 197 | 147 |
| Net income from continuing operations | 238 | 222 | 183 | 259 | 98 |
| Net income | 238 | 222 | 184 | 261 | 97 |